Let’s shape the future of biologics together
PEGS Europe 2025 brings together scientists advancing protein and antibody engineering. This year’s focus was on multispecific antibodies, ADC development, immuno-oncology, AI-/ML-driven design, and developability optimization.
We were excited to join the scientific dialogue alongside academic leaders, biotech innovators, and biopharma teams shaping the future of biologics. We were represented by a broad range of scientific experts, bringing deep experience in antibody discovery, protein design, and preclinical development.
Our teams contributed to discussions on cutting-edge methods ranging from phage and yeast display platforms to functional screening and in vivo validation strategies. We welcome the exchange of ideas and hope to explore new avenues of collaboration with you.
Featured Presentations
Rethinking Antibody Development to IND: Early Risk Mitigation, Target Specificity, & mRNA-LNP Delivery Strategies | Louise Brackenbury, Science Director - Advanced Modalities
Traditional pathways for antibody IND submission often overlook opportunities to mitigate risks early or accelerate candidate selection. This 30-minute presentation questions that approach by introducing more strategic, early decision points and examining alternative delivery platforms that could shift the development trajectory, especially in oncology.
You’ll learn how to:
- De-risk early with target specificity profiling using the proprietary Retrogenix® Cell Microarray, detecting unexpected off-target binding across thousands of human membrane proteins
- Leverage translationally relevant models for in vitro and in vivo pharmacology, improving predictive power before IND
- Integrate safety screening earlier to reduce late-stage attrition
- Explore a complementary delivery strategy using mRNA-LNP technology, unlocking new possibilities for solid tumor immunotherapy and improving scalability
Whether optimizing lead candidates or exploring novel delivery modalities, this session offers a fresh perspective on building a more agile and future-proof antibody development program.
Partner Presentation: CIS Display™ - A Fully in vitro Platform for Enhancing Small-format Discovery | Lurdes Rodrigues-Duarte, Director of R&D, Isogenica Ltd.
Small-format antibodies such as VHH are increasing in popularity thanks to clinical validation of the creative products that have been developed using these simple, robust building blocks. Like any antibody format, lead antibodies straight from primary screening are often of varied quality. In this talk, we explain how CIS Display™ can improve the quality of lead panels in terms of both affinities and developability characteristics, driven by ultra-high diversity libraries. When combined with NGS, we also explore how this higher diversity can be mined for additional sequence data to support both VHH discovery and downstream engineering objectives.
Featured Posters
| Safety Profile Assessment for IND-Enabling Studies: Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) | Namrata Jayanth, Research Leader |
| New Approach Methodologies (NAMs): Retrogenix® Technology for Rapid Early-Stage High-Throughput Screening and Toxicology Species Selection | Sarah Dawson, Senior Group Leader |